System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Ningshao Xia is an expert in Infectiology at Xiamen Hospital of Traditional Chinese Medicine (China). Ningshao Xia has authored 810 publications, the most recent in 2026, and is an investigator in 11 clinical trials, 1 of them ongoing. SLR score: 4,635 (community average: 125). How the SLR is computed.

LeadR Profile

Ningshao Xia Xiamen Hospital of Traditional Chinese Medicine China
4 635 ScienceLeadR Reputation 4635

Unlock

Register Login
Network Map

Infectiology

Subspecialties: Biochemistry - Pharmacy - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1995 - 2026
Source: PubMed

Xiamen University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 810

Citations

Citations: 26 718 1st author: 7 Last author: 472 Unique author: 0

Main journals

Nat Commun 33
Vaccine 29
Emerg Microbes Infect 25
Sheng Wu Gong Cheng Xue Bao 22
Bing Du Xue Bao 19

Best Journals

Signal Transduct Target Ther 6
Lancet Infect Dis 4
N Engl J Med 4

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Structural basis for cross-alphaherpesvirus neutralization by an antibody targeting a conserved hotspot on glycoprotein B.
PMID 42879282 — antibodies, neutralizing, glycoproteins, viruses		Cell Rep20260
Reoviridae-derived short trimerization domain for stabilizing homo-trimerization of vaccine immunogens and therapeutic proteins.
PMID 42928093 — vaccines, biological science disciplines, reoviridae, viruses, therapeutics		Nat Commun20260
Efficacy, safety, and immunogenicity of an Escherichia coli-produced nine-valent human papillomavirus vaccine: a multicentre, double-blind, randomised, controlled, phase 3 trial.
PMID 42379209 — escherichia, seroconversion, papillomavirus vaccines, safety, vaccines, vaccination, escherichia coli, alphapapillomavirus, communicable diseases, infections, persistent infection, human papillomavirus viruses		Lancet Infect Dis Top journal20262
Targeting mutant NPM1-expressing AML with T cell receptor-like antibodies.
PMID 42866624 — cells, antibodies, neoplasms, leukemia, myeloid, acute, t-lymphocytes, receptors, antigen, t-cell		iScience20260
An Engineered Spike Immunogen Drives Broad Protection of a Bivalent Recombinant Protein COVID-19 Vaccine in Animal Models.
PMID 42797806 — vaccines, covid-19 vaccines, virology, covid-19, recombinant proteins		Viruses20260

Clinical Studies 11

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 4
Phase 3 4
Phase 1 2
Phase 2 1

By status:

Completed 7
Active not recruiting 3
Recruiting 1

By type:

Interventional 8
Observational 3

By Monocentric/Multicentric:

monocentric 8
multicentric2to4 3
multicentric5to9 0
multicentricup10 0

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Plateau Antibody Levels of a Recombinant (E Coli) HPV Nonavalent Vaccine Versus Gardasil 9 in Young Women
NCT06197802 — papillomavirus vaccines, condylomata acuminata, vaccines, uterine cervical neoplasms, neoplasms, alphapapillomavirus, human papillomavirus viruses, female, women		N/AActive not recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS